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The potential of bacteriophage therapy to treat infections caused by antibiotic-resistant bacteria has now been well established
using various animal models. While numerous newly isolated bacteriophages have been claimed to be potential therapeutic can-
didates on the basis of in vitro observations, the parameters used to guide their choice among billions of available bacterio-
phages are still not clearly defined.Wemade use of a mouse lung infectionmodel and a bioluminescent strain of Pseudomonas
aeruginosa to compare the activities in vitro and in vivo of a set of nine different bacteriophages (PAK_P1, PAK_P2, PAK_P3,
PAK_P4, PAK_P5, CHA_P1, LBL3, LUZ19, and PhiKZ). For seven bacteriophages, a good correlation was found between in vitro
and in vivo activity. While the remaining two bacteriophages were active in vitro, they were not sufficiently active in vivo under
similar conditions to rescue infected animals. Based on the bioluminescence recorded at 2 and 8 h postinfection, we also define
for the first time a reliable index to predict treatment efficacy. Our results showed that the bacteriophages isolated directly on the
targeted host were the most efficient in vivo, supporting a personalized approach favoring an optimal treatment.
Bacteriophages are viruses that infect bacteria. They are wide-spread in the environment, and bacteriophage therapy—the
use of bacteriophages to treat bacterial infections—was first pro-
posed almost 100 years ago (1). With the increasing frequency of
antibiotic-resistant strains of pathogenic bacteria, there has been
renewed interest in bacteriophage therapy as a promising alterna-
tive (2). The state of the art and the pros and cons of bacteriophage
therapy have been extensively reviewed (3–6), and the data avail-
able for the current use of this approach to treat human patients in
Poland and Georgia are encouraging (7, 8).
In this context, more efforts than ever before are being made to
identify bacteriophages that infect various human pathogens, and
these bacteriophages are often proposed as potential candidates
for bacteriophage therapy as soon as their lytic nature has been
established in vitro (9, 10). However, additional information
should be obtained before considering the use of bacteriophages
in human treatments, but unfortunately, to date, there is still no
standardized method for evaluating the therapeutic potential of
bacteriophages. For instance, in a complex environment, such as
the human body, various factors (immune cells, enzymes, pep-
tides) may interfere with or even abolish bacteriophage activity,
potentially rendering bacteriophages poor therapeutic candidates
(11). The nature and presence of these factors also depend on the
infectious site that is targeted, as, for example, immune defenses
may vary between organs (12).
Host-virus interaction studies have suggested that the rate of
bacterial killing, the dose, and the presence of bacteriophage-en-
coded enzymes are determinants involved in treatment efficacy
(13–17). Such parameters would be best evaluated in a single spe-
cific animal model with various bacteriophages. Unfortunately, to
date, most studies assessing the efficacy of bacteriophages in ani-
mal models, including mice, sheep, cattle, pigs, and poultry (18–
23), have rarely considered more than one bacteriophage at a time.
Exceptions include a comparison of the replication pattern of two
virulent bacteriophages in the gut (24) and, more recently, an
evaluation of seven bacteriophages from two different classes in a
model assessing the in vivo dynamics of bacteriophage replication
(14). The few other studies conducted with several bacteriophages
at a time focused on the use of cocktails of bacteriophages rather
than comparisons of individual bacteriophages (25–27).
In this study, we compared nine bacteriophages infecting the
same host, Pseudomonas aeruginosa, a major pathogen causing
respiratory infections in immunodeficient individuals, including
80% of cystic fibrosis patients, for whom this bacterium consti-
tutes the main cause of morbidity (28). These nine bacterio-
phages, including six closely related bacteriophages and three bac-
teriophages from other, different genera, were compared to
PAK_P1, our reference bacteriophage previously reported to be
effective in treating acute lung infection in a mouse model (29).
The in vitro efficacy of each of these bacteriophages was compared
to its in vivo efficacy in our lung infection model, in which bio-
luminescence was used for the real-time monitoring of infection,
evidencing a good correlation between in vitro results and in vivo
efficacy for seven bacteriophages.
MATERIALS AND METHODS
Bacteriophages and bacterial strains used in this study. The bacterial
strains used in this work included the P. aeruginosa PAK strain, its biolu-
minescent version (PAK-lumi) (30), and the CHA strain (31).
TheMyoviridaePAK_P1 (accession no. KC862297) (29), PAK_P2 (ac-
cession no. KC862298), PAK_P3 (accession no. KC862299) (32), PAK_P4
(accession no. KC862300), and PAK_P5 (accession no. KC862301) bac-
teriophages (a group referred to as the PAK_Px bacteriophages) were
isolated from wastewater samples from the Paris, France, area with the
PAK strain as a host. The member of the Podoviridae LUZ19 (44 kb;
GenBank accession no. NC_010326.1) (33) and two members of the Myo-
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viridae, PhiKZ (280 kb; GenBank accession no. NC_004629.1) (34) and
LBL3 (64 kb; GenBank accession no. NC_011165.1) (35), were amplified
on strains PAO1 (LUZ19 and PhiKZ) and Aa245 (LBL3). The CHA_P1
bacteriophage (accession no. KC862295) was isolated from wastewater
using the CHA strain (31). Briefly, for each bacteriophage, a 1-liter culture
of the host (optical density [OD] at 600 nm in LB, 0.1) was infected with
the given bacteriophage at a multiplicity of infection (MOI) of 0.001 and
incubated at 37°C with shaking. Once lysis had occurred and the OD at
600 nm returned to a value below 0.1, the lysate was filter sterilized with
two in-line filters (pore sizes, 0.8 to 0.45 and 0.2 to 0.1m; Sartopore 300;
Sartorius) and concentrated with an ultrafiltration cassette (Vivaflow 200;
Sartorius). The concentrates were then ultracentrifuged twice on cesium
chloride gradients (36). The resulting solutions were then dialyzed against
Tris buffer (10 mM Tris, 150 mM NaCl, pH 7.5), mixed with 0.03%
gelatin, and stored at 4°C. CHA_P1 adaptation to the PAK strain was
carried out as previously described (32). A detailed analysis of the PAK-Px
genomes will be published elsewhere (M. Henry, L. M. Bobay, A. Che-
vallereau, E. Saussereau, P. J. Ceyssens, and L. Debarbieux, unpublished
data).
In vitro tests. Efficiency of plating (EOP) was determined on the same
day on both the PAK-lumi strain and the original hosts for each bacterio-
phage using the standard plaque assay method. The EOP was calculated as
the ratio of the number of plaques formed by each bacteriophage on the
PAK-lumi strain to the number of plaques formed on its host. Lysis kinet-
ics for each bacteriophage in liquid LB medium were performed using an
MOI of 0.001, which represents the condition for which the clearest dis-
tinction between the different bacteriophages could be observed, and were
determined using a 96-well plate reader (37).
Ethics statement. Eight-week-old BALB/c male mice (Janvier) were
housed in animal facilities in accordance with French and European reg-
ulations on the care and protection of laboratory animals. Protocols were
approved by the veterinary staff of the Institut Pasteur animal facility
(approval number 10.565) and the National Ethics Committee (approval
number 2012-0018).
In vivo tests. Mice were infected by intranasal instillation of 1  107
CFU of PAK-lumi in 50 l of PBS, following anesthesia by intramuscular
injection of a mixture of ketamine and xylazine. Two hours later, the
animals were treated by the same route with 30 l of phosphate-buffered
saline (PBS) or bacteriophage solution, following anesthesia by isoflurane
inhalation delivered by an IVIS 100 imaging system (PerkinElmer). The
titration of bacteriophage stocks was performed on the day before each
experiment, and the exact bacteriophage dose given was also checked, to
ensure that the MOI used was as accurate as possible. The survival and
weight of the animals as well as the aspect of their fur and their motility
were monitored daily for 13 days after infection. In accordance with the
ethics policy relating to this protocol, the animals were euthanized when
they were moribund or after they had lost more than 25% of their initial
body weight.
Luminescence measurements. Luminescence was recorded as previ-
ously described by counting photons within a constant defined area cor-
responding to the surface of the chest and encompassing the whole lung
region (29). All data were normalized by subtracting the background level
obtained from a noninfected control animal included in each recording.
Luminescence was measured for all animals at 2, 4, 6, and 8 h postinfec-
tion and then once every 2 days over a 13-day period. The ratio of the
luminescence measurement at 8 h after infection to that at 2 h after infec-
tion was calculated as follows: the mean radiance value obtained for the
noninfected animal was subtracted from the mean radiance value ob-
tained for each animal of each group. The median value was then deter-
mined for each group for the 2- and 8-h-postinfection time points and
used to calculate the ratio (luminescence at 8 h/luminescence at 2 h).
RESULTS
Isolation of PAK_Px bacteriophages. Bacteriophages infecting
the PAK strain of P. aeruginosa were isolated from five environ-
mental sources on the same day. Plaque morphology was used to
select 16 candidates, from which we isolated genomic DNA. Re-
striction digestion of the DNA yielded five different restriction
patterns. One representative of each pattern was chosen for fur-
ther characterization and named PAK_P1 to PAK_P5 (here re-
ferred to as the PAK_Px bacteriophages). Only PAK_P1 and
PAK_P2 originated from the same environmental source. The
CHA_P1 bacteriophage was also later isolated from an environ-
mental source, using as the host P. aeruginosa strain CHA, a clin-
ical strain isolated from a cystic fibrosis patient (31). The genome
sequences obtained for these bacteriophages showed that they
formed two distinct subgroups, the first comprising PAK_P1,
PAK_P2, and PAK_P4 and the second comprising PAK_P3,
PAK_P5, and CHA_P1 (Table 1). A detailed analysis of these
genomic sequences will be published elsewhere.
EOP and lysis kinetics. We first selected eight bacteriophages
and evaluated their ability to form plaques on our model strain
PAK-lumi of P. aeruginosa by determining their EOP on this
strain. EOP was set to 1 for the PAK_Px bacteriophages and was
found to be 0.8 for LBL3 and 0.2 for LUZ19. PhiKZ had an EOP of
1.2, as more plaques were observed on the PAK-lumi strain than
on the strain used for its propagation, PAO1.
We then determined the lysis kinetics of these eight different
bacteriophages on the PAK-lumi strain at the same MOI in liquid
medium (Fig. 1A). The OD decreased after approximately 70 min
of incubation for all the PAK_Px bacteriophages. However, we
were able to differentiate two clusters within this group, the first
consisting of PAK_P1, PAK_P2, and PAK_P4, for which the OD
value reached 0.04 before being affected by bacterial lysis, and the
second consisting of PAK_P3 and PAK_P5, for which the OD
value reached 0.055 (Fig. 1A, inset). The time lag to a decrease in
TABLE 1 Main characteristics of bacteriophages used in this study
Family Genus Name Size (kb) Host EOPa Accession no.
Myoviridae Unclassified PAK_P1 93 PAK 1 KC862297
Unclassified PAK_P2 91 PAK 1 KC862298
Unclassified PAK_P4 93 PAK 1 KC862300
Unclassified PAK_P3 88 PAK 1 KC862299
Unclassified PAK_P5 85 PAK 1 KC862301
Unclassified CHA_P1 88 CHA 0.5 KC862295
Pbunalikevirus LBL3 64 Aa245 0.8 NC_011165.1
Phikzlikevirus PhiKZ 280 PAO1 1.2 NC_004629.1
Podoviridae Phikmvlikevirus LUZ19 44 PAO1 0.2 NC_010326.1
a EOP values obtained on the PAK-lumi strain.
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the OD was the greatest for LUZ19 (about 270 min), suggesting
that lysis occurred more slowly with this bacteriophage, whereas
lysis occurred slightly more rapidly with PhiKZ and LBL3 (210
and 180 min, respectively).
Comparison of in vivo efficacies and short-term kinetics for
curative bacteriophage treatments. We used the previously de-
scribed bacteriophage PAK_P1 (29) as the reference for this study
and refined the treatment dose for this phage to an MOI of 0.1 to
obtain a survival rate of about 75%, making it possible to distin-
guish between bacteriophages with potentially higher or lower
efficacies.
Using MOIs of between 0.05 and 0.2, we twice independently
tested each of the bacteriophages (PAK_P2 to PAK_P5, LBL3,
PhiKZ, and LUZ19) following the same procedure, with PAK_P1
FIG 1 In vitro and in vivo activities of P. aeruginosa bacteriophages. (A) Individual in vitro lysis kinetics for the indicated bacteriophages at an MOI of 0.001 on
the PAK-lumi strain (values are means of 4 replicates; only one set of data representative of 3 independent experiments is shown); (B) survival curves of the groups
of animals infected with PAK-lumi and treated with the indicated bacteriophages at an MOI of 0.1. For each group of mice, the results shown are from at least
two independent experiments (n 8 to 16 animals).
In Vitro versus In Vivo Phage Efﬁcacies
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and PBS included in each experiment as controls. The PAK_Px
bacteriophages gave the highest survival rates, between 75 and
100% (Fig. 1B). We obtained survival rates of 50% for LBL3, 37%
for LUZ19, and 15% for PhiKZ, a rate similar to that obtained with
the PBS control.
By recording bioluminescence every 2 h for the first 8 h after
infection, we were able to compare the short-term in vivo kinetics
of treatments with the different bacteriophages by quantifying the
luminescence emitted from the chest area of the animals (Fig. 2A
and B). In all the groups, luminescence increased between 2 and 4
h after infection, confirming the active development of the infec-
tion in the lungs. A comparison of the median values of each series
between 4 and 6 h after infection (i.e., between 2 and 4 h after
bacteriophage treatment) showed a decrease in luminescence in
FIG 2 Short-term kinetics of bacteriophage treatments following infection with a lethal dose of the PAK-lumi strain (A) Representative images obtained at 2 and
8 h postinfection for groups treated with PBS, PAK_P1, or PhiKZ. The animal on the far left of each image is the noninfected mouse used for background light
measurement. The scale was normalized to allow visual comparison. p/s/cm2/sr, number of photons per second per square centimeter per steradian. (B) Average
radiances for all the animals used in this study at each time point, with medians and interquartile range indicated. (C) Ratios of the median average radiance values
at 8 h to those at 2 h for each group of mice.
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the animals treated with the bacteriophages of the PAK_Px group
(Fig. 2B). For LBL3, luminescence did not begin to decrease until
6 h postinfection. For LUZ19, a decrease in the amount of light
emitted was observed between 4 and 8 h after infection, and for
PhiKZ, the light emitted from the chest area increased steadily
during the first 8 h after infection, as for the PBS group (Fig. 2B).
Based on these quantifications and the survival rates obtained, we
hypothesized that the amount of light emitted during the first 8 h
of infection could be used to anticipate the overall in vivo efficacy
of a given bacteriophage by defining a predictive index from the
ratio of the luminescence values obtained at 2 and 8 h postinfec-
tion. The luminescence measured at 2 h reflected the bacterial load
at the time of treatment, whereas the largest differences in lumi-
nescence between groups were revealed at the 8 h time point. By
plotting values of this ratio on a graph, we could discriminate
bacteriophage-treated groups into two profiles: the first, with ratio
values falling below 3, corresponded to the groups of animals for
which bacteriophage treatment resulted in survival rates of at least
75%. The second, for which ratio values remained above 3, corre-
sponded to the groups for which bacteriophage treatment resulted
in the survival of no more than 50% of the animals (Fig. 2C). A
ratio value of 3 was then chosen as the index to discriminate bac-
teriophages on the basis of in vivo efficacy.
Conflicting results in vitro and in vivo for bacteriophage
PhiKZ. In vitro (EOP, lysis kinetics) and in vivo efficiencies were
highly correlated for all bacteriophages except PhiKZ. Despite
having an EOP of 1.2 on the PAK-lumi strain and reasonably good
lysis kinetics, survival rates following treatment with PhiKZ were
as low as those for PBS when animals were infected at an MOI of
0.1 (Fig. 1B). We investigated the possibility that this bacterio-
phage was devoid of activity in vivo by treating animals with a
higher dose (MOI, 20). The survival curves obtained in two inde-
pendent experiments (Fig. 3B) revealed a dose-dependent effect,
as 100% of the animals treated with PhiKZ at an MOI of 20 sur-
vived acute infections and displayed a luminescence pattern sim-
ilar to that obtained for the reference bacteriophage, PAK_P1 (Fig.
3A). In addition, the ratio values calculated from data obtained in
these experiments were shown to be consistent with the survival
rates obtained (Fig. 3C).
Assessing the reliability of the predictive index. First con-
firmed by the above-described experiments with PhiKZ, we fur-
ther assessed the robustness of the index and its applicability to
new bacteriophages using CHA_P1, a bacteriophage infecting
strain CHA whose genome revealed close similarity to the
PAK_P3 genome (these bacteriophages share 90% homology in
their proteins). The CHA_P1 bacteriophage, shown to rescue
CHA-infected mice, was also able to infect the PAK-lumi strain
with an EOP of 0.5 (Fig. 4 and Table 1). The lysis kinetics for
CHA_P1 were similar to those for the PAK_Px bacteriophages,
although lysis was slightly less rapid (Fig. 5A). These favorable in
vitro results were not confirmed when CHA_P1 was tested in vivo.
Surprisingly, luminescence analysis and the calculated ratio of
emitted light allowed us to anticipate a low in vivo efficacy for
CHA_P1 with a value far above the index (Fig. 5B and 3C), which
was confirmed by the death of all the treated animals at the end of
the experiment (Fig. 5C). We then hypothesized that amplifying
this bacteriophage on the PAK strain might increase its efficacy in
vivo, as previously demonstrated for the in vitro adaptation of the
PAK_P3 bacteriophage to the CHA strain (32). However, five suc-
cessive passages on the PAK strain did not significantly increase
the EOP on the PAK strain (while the EOP on CHA remained
unchanged) or the in vivo efficacy of the adapted CHA_P1 bacte-
riophage against this strain (the survival rate stayed below 25%
with treatment at an MOI of 0.1).
DISCUSSION
Do all bacteriophages forming plaques on a bacterial lawn qualify
as therapeutic candidates? From theoretical studies, several pa-
rameters have been proposed to be indicative of the in vivo activity
of bacteriophages (17, 38), but to our knowledge, only one study
has recently tried to tackle this question using an animal model
(14). However, in the aforementioned study, bacteriophage and
bacterial solutions were simultaneously intramuscularly injected
into mice either separately or mixed, leading to the rapid adsorp-
tion of bacteriophages to their bacterial host before the infection
proceeded. Such a protocol, set for kinetic studies, was not directly
relevant to comparison of therapeutic efficacies, as the infection
had not started before the treatment was applied. Other studies
have also shown in the gut, for example, that it proved difficult to
FIG 3 Short-term kinetics and survival curves for PhiKZ-treated mice in-
fected with the PAK-lumi strain. (A, B) Luminescence measurements and
survival rates of the groups of mice treated with PhiKZ at the indicated MOIs;
(C) ratios of radiance at 8 h postinfection to that at 2 h postinfection in groups
treated with PhiKZ and CHA_P1 at the indicated MOIs. For each group, the
results shown are from two independent experiments (n 8 to 12).
In Vitro versus In Vivo Phage Efﬁcacies
December 2013 Volume 57 Number 12 aac.asm.org 5965
 o
n







predict the in vivo efficacy of bacteriophages from in vitro obser-
vations (24, 37, 39).
Using a single bacterial host, a well-established mouse lung
infection model, a real-time imaging system, and a treatment
strategy that could be adapted to humans in a context of active
therapy (minimal dose and an effect relying on the amplification
of the bacteriophage on the site of the infection), we evaluated the
in vitro and in vivo efficacies of a set of nine bacteriophages from
various genera.
While exploiting the bioluminescence data, the ratio of light
emitted at 2 h to that emitted at 8 h following infection allowed us
to discriminate between the most and the least efficient bacterio-
phages in vivo. An index value of 3 was then proposed as a refer-
ence to classify these bacteriophages into two groups. We noticed
that this index appeared to be reliable, despite the high variability
of the ratio values obtained from different rounds of experiments,
a characteristic of in vivo experimentation (see the results for the
PBS groups in both Fig. 2C and 3C). Interestingly, this index al-
lowed us to anticipate the rate of survival as the final outcome of
the animal trial, which provides an opportunity to reduce the time
and cost of future experiments.
Despite various host factors (naturally present or induced by
the infection, such as immune cells) that could jeopardize the
success of bacteriophage treatments, we observed a correlation
between in vitro and in vivo efficacy for most of the bacteriophages
studied here (with the exception of PhiKZ and CHA_P1). In vitro
and in vivo results were well correlated for the PAK_Px bacterio-
phages. Among these, variations in efficacy in vivo reflected their
genetic relatedness (PAK_P3 and PAK_P5 are genetically closely
related to each other, as are PAK_P1, PAK_P2, and PAK_P4;
Henry et al., unpublished). In vitro and in vivo results were also
well correlated for LBL3 and LUZ19, which were less efficient
under both conditions, thus showing that for the majority of bac-
teriophages considered in this study, in vitro data were indicative
of in vivo efficacy.
Moreover, the optimal efficacy achieved with the bacterio-
phages isolated on the strain used in the animal model highlights a
possible effect of the bacterial host used for isolation on the effi-
cacy of the treatment. This was further supported by the use of
CHA_P1, a bacteriophage which is genetically closely related to
PAK_P3 and PAK_P5, although it was isolated using the CHA
FIG4 In vivo efficacy of the CHA_P1 bacteriophage in CHA-infected animals.
Survival curves are for the groups of animals infected with CHA_P1 (4 106
CFU) and treated with the CHA_P1 bacteriophage at the indicated MOIs (n
4 to 8).
FIG 5 In vitro and in vivo efficacies of the CHA_P1 bacteriophage on the
PAK-lumi strain. (A) Individual lysis kinetics for the indicated bacteriophages
at an MOI of 0.001 (values are means of 4 replicates; only one set of data
representative of 3 independent experiments is shown) on the PAK-lumi
strain; (B) average radiances of the animals used for the evaluation of CHA_P1
treatment at an MOI of 0.1, with medians and interquartile ranges indicated;
(C) survival curves of the groups of animals infected with PAK-lumi and
treated with the indicated bacteriophages at an MOI of 0.1.
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strain as a host, suggesting that bacteriophages presenting the best
chances to be efficient in vivo are likely to be those isolated on
purpose. Despite this genetic closeness and kinetics of lysis similar
to that of PAK_Px, CHA_P1 was unable to cure animals infected
with the PAK-lumi strain. In addition, an attempt to adapt this
bacteriophage to the PAK strain failed, with neither an increase in
EOP nor an improvement in in vivo efficacy being achieved. In
contrast, CHA_P1 was able to rescue CHA-infected mice, show-
ing that this bacteriophage is nonetheless able to reach and infect
bacteria in vivo. Similarly, the lack of in vivo efficacy of the PhiKZ
bacteriophage could not be accounted for by an intrinsic inability
to infect bacteria in vivo, since increasing the treatment dose al-
lowed maximum efficacy to be reached. These observations war-
rant further investigation of the factors which are preventing the
CHA_P1 bacteriophage from being efficient in PAK-infected an-
imals. These factors could be linked either to the animal host re-
sponse toward a different bacterial pathogen or to the bacterium
itself. For example, the PAK strain could, in vivo, repress the ex-
pression of a protein required for an optimal infectious cycle of
CHA_P1 but not required by the PAK_Px bacteriophages. Our
results therefore show that in vitro efficacy, although necessary, is
not sufficient to ensure in vivo efficacy.
To conclude, the results of this study, which for the first time
compares the in vivo efficacy of various bacteriophages, whether
or not they are specifically isolated using the targeted host, illus-
trate the two complementary strategies currently proposed for use
in the development of bacteriophage therapy (40, 41). Depending
on the type of infection targeted (chronic or acute) and the patient
clinical state, the use of prêt à porter (ready-to-use) cocktails aim-
ing to secure minimal efficacy may then be preferred or not over
sur mesure (personalized) therapy (isolation of bacteriophages us-
ing the strain from the patient). The latter is more time consum-
ing, but on the basis of our data suggesting a link between in vivo
efficacy and the host of isolation, it is favored for optimum effi-
ciency. Our findings may also shed light on possible reasons for
the failure of certain bacteriophage therapy trials (experimental or
human) when bacteriophages are selected solely on the basis of in
vitrodata. This means that the inability of a bacteriophage active in
vitro to work in a clinical trial may not imply that the phage ther-
apy treatment cannot work.
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